抗血管生成和巨噬细胞为基础的神经胶质瘤免疫治疗策略。

IF 2.7 3区医学 Q2 CLINICAL NEUROLOGY

Brain Tumor Pathology Pub Date : 2021-07-01 Epub Date: 2021-05-11 DOI:10.1007/s10014-021-00402-5

Eiichi Ishikawa, Tsubasa Miyazaki, Shingo Takano, Hiroyoshi Akutsu

{"title":"抗血管生成和巨噬细胞为基础的神经胶质瘤免疫治疗策略。","authors":"Eiichi Ishikawa, Tsubasa Miyazaki, Shingo Takano, Hiroyoshi Akutsu","doi":"10.1007/s10014-021-00402-5","DOIUrl":null,"url":null,"abstract":"As a new concept of glioma therapy, immunotherapy combined with standard therapies is a promising modality to improve glioma patient survival. VEGF and its signaling pathway molecules not only inhibit angiogenesis but also may reinforce the immunosuppressive tumor microenvironment, including promotion of the accumulation of immunosuppressive tumor-associated macrophages (TAMs). In this review, we discuss VEGF-targeted therapy as a new treatment option of the TAM-targeted therapy for high-grade gliomas, as well as other TAM-targeted therapies. The authors also discuss the potential of these therapies combined with conventional immunotherapies.","PeriodicalId":9226,"journal":{"name":"Brain Tumor Pathology","volume":"38 3","pages":"149-155"},"PeriodicalIF":2.7000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10014-021-00402-5","citationCount":"8","resultStr":"{\"title\":\"Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.\",\"authors\":\"Eiichi Ishikawa, Tsubasa Miyazaki, Shingo Takano, Hiroyoshi Akutsu\",\"doi\":\"10.1007/s10014-021-00402-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As a new concept of glioma therapy, immunotherapy combined with standard therapies is a promising modality to improve glioma patient survival. VEGF and its signaling pathway molecules not only inhibit angiogenesis but also may reinforce the immunosuppressive tumor microenvironment, including promotion of the accumulation of immunosuppressive tumor-associated macrophages (TAMs). In this review, we discuss VEGF-targeted therapy as a new treatment option of the TAM-targeted therapy for high-grade gliomas, as well as other TAM-targeted therapies. The authors also discuss the potential of these therapies combined with conventional immunotherapies.\",\"PeriodicalId\":9226,\"journal\":{\"name\":\"Brain Tumor Pathology\",\"volume\":\"38 3\",\"pages\":\"149-155\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s10014-021-00402-5\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain Tumor Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10014-021-00402-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/5/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Tumor Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10014-021-00402-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 8

摘要

免疫治疗联合标准治疗作为胶质瘤治疗的新理念，有望提高胶质瘤患者的生存率。VEGF及其信号通路分子不仅抑制血管生成，还可能增强免疫抑制性肿瘤微环境，包括促进免疫抑制性肿瘤相关巨噬细胞(tam)的积累。在这篇综述中，我们讨论了vegf靶向治疗作为tam靶向治疗高级别胶质瘤的新治疗选择，以及其他tam靶向治疗。作者还讨论了这些疗法与常规免疫疗法结合的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.

As a new concept of glioma therapy, immunotherapy combined with standard therapies is a promising modality to improve glioma patient survival. VEGF and its signaling pathway molecules not only inhibit angiogenesis but also may reinforce the immunosuppressive tumor microenvironment, including promotion of the accumulation of immunosuppressive tumor-associated macrophages (TAMs). In this review, we discuss VEGF-targeted therapy as a new treatment option of the TAM-targeted therapy for high-grade gliomas, as well as other TAM-targeted therapies. The authors also discuss the potential of these therapies combined with conventional immunotherapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brain Tumor Pathology 医学-病理学

CiteScore

5.40

自引率

9.10%

发文量

审稿时长

>12 weeks

期刊介绍： Brain Tumor Pathology is the official journal of the Japan Society of Brain Tumor Pathology. This international journal documents the latest research and topical debate in all clinical and experimental fields relating to brain tumors, especially brain tumor pathology. The journal has been published since 1983 and has been recognized worldwide as a unique journal of high quality. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. The journal publishes original articles, case reports, rapid short communications, instructional lectures, review articles, letters to the editor, and topics.Review articles and Topics may be recommended at the annual meeting of the Japan Society of Brain Tumor Pathology. All contributions should be aimed at promoting international scientific collaboration.